Debra Silberg

Debra Silberg, MD, PhD, FACG is an accomplished life sciences executive with deep experience across all stages of drug development. She serves as a Scientific Advisor to multiple pharmaceutical companies. She is currently a Scientific Advisor and on the Board of Directors of Ellodi Pharmaceuticals. She has held clinical leadership roles at AstraZeneca, Shire, and Takeda, where she served as the company’s Global Vice President of Clinical Development and Clinical Science Head for Gastroenterology. In this role, she was responsible for the Gastrointestinal (GI) program team, which included approximately 30 physicians and clinical scientists across the US, Europe, China, and Japan who were focused on several GI diseases, including celiac disease. Additionally, Dr. Silberg oversaw the clinical aspects and led discussions with regulatory authorities (FDA and EMA) to facilitate the advancement of numerous GI development programs. Dr. Silberg earned her BS degree at the University of Michigan, her PhD in Immunology from Wayne State University School of Medicine, and her MD from Albert Einstein College of Medicine. She completed her Internal Medicine Residency and Gastroenterology Fellowship at the University of Pennsylvania Health System. She then became a faculty member in the Department of Medicine, Division of Gastroenterology at the University of Pennsylvania where she treated patients and was the principal investigator of a National Institutes of Health (NIH) funded molecular biology laboratory. Dr. Silberg has been the recipient of seven NIH grants, published over 40 peer-reviewed articles, served on numerous national scientific committees, and is a fellow of the American College of Gastroenterology.